Skip to main content
Stanley Lewis

Stanley Lewis, MD, MPH

Founder and CEO, A28 Therapeutics
Dr. Lewis is a proven leader in life sciences, with 25 years of experience in clinical research, drug development, patient care and teaching. He founded A28 Therapeutics in 2021 and serves as Chief Executive Officer. Previously, Dr. Lewis served as Chief Medical Officer and in various clinical development roles, most recently as CMO of Ansun Biopharma where he successfully led the company’s late-stage clinical trials of therapies for parainfluenza, influenza, and COVID-19, anchored its fundraising team on the way to securing $100M in Series B financing, and provided strategic leadership on the company’s in-licensing efforts. Prior to joining Ansun, Dr. Lewis was CMO at TaiMed Biologics where he led the company to US FDA approval of TROGARZO™, the first long-acting agent and the first monoclonal antibody treatment for multi-drug resistant HIV disease. He was instrumental in securing additional regulatory designations and grant funding, as well as manufacturing and commercial licensing for TaiMed development programs. Dr. Lewis serves on multiple scientific and medical advisory boards for both for-profit and non-profit organizations focused on improving healthcare, clinical research, and education. Dr. Lewis is a graduate of the University of Texas McGovern Medical School where he completed his internship, residency, and fellowship in Internal Medicine. He also earned a Master’s in Public Health while serving as Assistant Professor of Medicine in the Department of Internal Medicine. Dr. Lewis completed his undergraduate education at the University of Texas at Austin. Dr. Lewis has published dozens of peer-reviewed articles, holds multiple patents and patents pending, and has been a principal or co-investigator on numerous Phase 1-4 clinical trials.